CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Triple negative breast cancer (TNBC) lacks estrogen receptor (ER), progesterone receptor (PR), and HER-2 expression, rendering it unresponsive to hormone therapies.
• TNBC is an aggressive breast cancer subtype with poorer prognoses and frequent systemic relapse despite conventional chemotherapy.
• Current treatment strategies for TNBC include neoadjuvant and adjuvant therapies, with emerging options targeting PD-L1-positive tumors and PARP inhibitors for BRCA-mutated cases.

Purpose of the Study:

• To review current therapeutic approaches for triple negative breast cancer (TNBC).
• To discuss recent advancements in TNBC treatment, including immunotherapy and targeted therapies.
• To evaluate the preclinical data and ongoing clinical trials of cyclin-dependent kinase (CDK) 4/6 inhibitors in TNBC.

Main Methods:

• Review of preclinical data on CDK 4/6 inhibitors.
• Analysis of current clinical trials investigating CDK 4/6 inhibitors in TNBC.
• Discussion of existing TNBC treatment modalities and novel therapeutic targets.

Main Results:

• CDK 4/6 inhibitors have shown significant improvements in progression-free survival in ER-positive breast cancers.
• Preclinical data suggests potential efficacy of CDK 4/6 inhibitors in TNBC.
• Ongoing clinical trials are actively assessing the role of CDK 4/6 inhibitors in TNBC treatment.

Conclusions:

• Novel therapeutic strategies are urgently needed for triple negative breast cancer (TNBC).
• CDK 4/6 inhibitors represent a promising targeted therapy for TNBC, with ongoing research evaluating their clinical utility.
• The integration of CDK 4/6 inhibitors could potentially improve outcomes for TNBC patients.